Department of Radiation Oncology, Indiana University School of Medicine, 535 Barnhill Dr, RT 041, Indianapolis, IN, 46202, USA.
Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA.
Sci Rep. 2024 Jul 31;14(1):17710. doi: 10.1038/s41598-024-68351-5.
The purpose of this study is to examine the effect of early incomplete follow-up on overall survival among stage I lung cancer patients. Patients with clinical stage I lung cancer at our institution between 2007 and 2016 were identified (N = 1111). Exclusions included < 18 years of age (N = 2), missing stage or demographics (N = 56), incomplete appointment data or had only one scheduled appointment (N = 351), or did not survive for at least 1 year after diagnosis (N = 120). Missed appointments were defined as unattended follow-up appointments within the first year of diagnosis without an attended appointment in the subsequent 60 days. The primary outcome was the hazard ratio (HR) for death associated per 10% increase in missed oncology follow-up appointments. Univariable and descriptive statistics were performed, and a multivariable landmark Cox regression model was created to examine the effect of missed oncology follow-up on survival. A total of 582 patients were analyzed with median follow-up of 3.2 years and median age of 69 years. On multivariable analysis controlling for age, sex, race, insurance status, and definitive treatment type the HR for death was 1.44 (95% CI 1.05-1.97) for every 10% increase in missed appointments. Incomplete oncologic follow-up may negatively impact overall survival among survivors of early-stage lung cancer.
本研究旨在探讨早期不完全随访对 I 期肺癌患者总生存的影响。本研究纳入了 2007 年至 2016 年期间在我院就诊的临床 I 期肺癌患者(N=1111)。排除标准包括年龄<18 岁(N=2)、分期或人口统计学资料缺失(N=56)、预约数据不完整或仅预约一次(N=351)、或诊断后至少 1 年未存活(N=120)。失约定义为在诊断后 1 年内未参加随访预约,且在随后的 60 天内无预约。主要结局是每增加 10%错过肿瘤学随访预约与死亡相关的风险比(HR)。进行了单变量和描述性统计分析,并创建了多变量里程碑 Cox 回归模型,以检验错过肿瘤学随访对生存的影响。共分析了 582 例患者,中位随访时间为 3.2 年,中位年龄为 69 岁。在多变量分析中,在校正年龄、性别、种族、保险状况和明确治疗类型后,错过预约的患者死亡风险比(HR)为 1.44(95%CI 1.05-1.97)。不完全的肿瘤学随访可能会对早期肺癌幸存者的总生存产生负面影响。